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Hematopoietic stem cell (HSC) transplantation has curative potential for patients with hematological ma-
lignancies. Clinically, HSCs derived from mobilized peripheral blood are used more frequently than bone
marrow. However, current standard mobilizing agents yield grafts that may not contain sufﬁcient HSCs. Here,
using murine models, we discovered that FLT3L synergized with plerixafor to mobilize phenotypically
deﬁned HSCs and their combination (FP) was superior to granulocyte colony-stimulating factor (G-CSF) alone
or in combination with plerixafor (GP). Additionally, FP mobilized more regulatory T cells, natural killer cells,
and plasmacytoid dendritic cells compared with G-CSF alone or GP. Both syngeneic and allogeneic grafts
mobilized by FP led to long-term survival in transplanted mice. Collectively, FP represents a promising novel
and potent mobilization regimen with potential clinical application in both the autologous and allogeneic
transplantation settings.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION suggesting that combining plerixafor with other agents may
Hematological malignancies contribute to almost 10% of
the mortalities caused by cancers in the United States [1].
Hematopoietic stem cell transplantation (HSCT) is a well-
established treatment with curative potential for a variety
of hematological cancers. In addition to bone marrow
transplantation (BMT), mobilized peripheral blood provides
a rich source of HSCs for transplantation. Successful HSCT
depends on a mobilization regimen that provides an
adequate number of HSCs for engraftment but is less likely to
provoke transplant-related complications. However, current
mobilization regimens occasionally do not mobilize sufﬁ-
cient numbers of cells into the peripheral blood, or the
mobilized immune cells often lead to post-transplant com-
plications, such as graft-versus-host disease (GVHD).
The CXCR4 antagonist plerixafor (Mozobil) induces safe
and rapidmobilization of clinical grafts capable of promoting
robust hematopoietic recovery in HSCT patients [2]. How-
ever, the number of hematopoietic stem/progenitor cells
(CD34þ cells) mobilized by plerixafor alone is far lower than
thosemobilized by granulocyte colony-stimulating factor (G-
CSF), the current gold standard mobilizing regimen,edgments on page 313.
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FLT3 ligand (FLT3L) is a stem-cell speciﬁc growth factor
that expands and may also mobilize stem cells in mice after
administration for 10 days, either as a single agent or in
combination with other molecules such as IL-8 and G-CSF
[3,4]. Most recently, FLT3L has been introduced into a clinical
trial, demonstrating that the administration of FLT3L on a
consecutive 5- or 10-day schedule effectively mobilizes
CD34þ HSCs in healthy donors [5].
Here we tested the effect of the combination of 2 clinical-
grade drugs, FLT3L and plerixafor, on stem cell mobilization
and evaluated transplantation outcomes of mobilized cells in
both syngeneic and allogeneic murine models. Our data
demonstrate that the combination of FLT3L and plerixafor is
a promising regimen for mobilizing adequate stem cells and
other cell subsets that lead to better engraftment and sur-
vival after both syngeneic and allogeneic transplantation.
METHODS
Mice
BALB/c and C57BL/6 mice, 8 to 10 weeks old, were purchased from the
National Cancer Institute (Frederick, MD). All animal work was approved by
the Ohio State University Animal Care and Use Committee, and mice were
treated in accordance with the institutional guidelines for animal care.
Cell Mobilization
C57BL/6micewere injected i.p. with recombinant human FLT3L (Celldex
Therapeutics, Needham, MA or Miltenyi Biotec Auburn, CA) (350 mg/kg/day)
for 10 consecutive days or G-CSF (Amgen, Thousand Oaks, CA) (150 mg/kg/
day) for 5 consecutive days. Twelve hours after the last dose of FLT3L orTransplantation.
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Louis, MO) (5 mg/kg) and killed 1 hour later. Peripheral blood was collected
retro-orbitally while mice were under deep anesthesia, as described previ-
ously [6]. In detail, mice were killed by i.p. injectionwith 100 uL of a mixture
of ketamine (54.3 mg/mL) and xylazine (9.1 mg/mL). Blood was collected
from the retro-orbital venous plexus through a microcapillary heparinized
tube, and mice were then killed while still deeply anesthetized. RBCs were
depleted by RBC lysis buffer. The remaining cells were subjected to ﬂow
cytometric analysis or transplantation. The capacity of human FLT3L to bind
murine Flt3 receptors and plerixafor to block murine Cxcr4 receptor was
previously reported [7-10].
Transplantation
For syngeneic transplantation, C57BL/6 mice were subjected to 9 Gy of
irradiation delivered in 2 fractions separated by 4 hours using RS 2000 X-Ray
Irradiator (Rad Source Technologies, Suwanee, GA). Four hours later, each
mouse was transplanted via the tail vein with 2  105 mobilized RBC-
depleted peripheral blood cells from C57BL/6 mice. For allogeneic trans-
plantation, the recipient BALB/c mice were subjected to a lethal irradiation
(delivered as aforementioned) and injected with 8  105 mobilized RBC-
depleted peripheral blood cells per mouse isolated from C57BL/6 mice.
The rationale of using these cell numbers for transplantation is based on
previous studies demonstrating that about 90% of mice survived when
syngeneically infused with 1  106 peripheral nucleated cells mobilized by
G-CSF [11,12], but only around 17% of mice survived if 2.5  105 cells
mobilized by G-CSF were transplanted [12]. Therefore, for syngeneic
transplants, 2 105 mobilized cells were used in our experiments to explore
whether the combination of FLT3L and plerixafor has an advantage over G-
CSF with a greater mobilizing potential. For allogeneic transplants, a 4-fold
higher number of cells (ie, 8  105 donor cells isolated from C57BL/6 mice)
were administered i.v. into each BALB/c recipient, considering the likely
graft rejection and GVHD complication in the allogeneic model. The lethally
irradiated mice were housed in a sterile environment, and baytril antibiotic
was provided in the drinking water to prevent infection-caused mortality.
After transplantation, mice were monitored daily and the phenotypes of the
dying mice were recorded.
Colony Formation Assay
Colony formation assays were performed using MethoCult GF M3434
(StemCell Technologies, Vancouver, British Columbia, Canada) according to
the manufacturer’s instructions. Brieﬂy, 4.6  104 of mobilized WBCs were
resuspended in .3 mL Iscove’s modiﬁed Dulbecco’s media (Life Technologies,
Grand Island, NY) with 2% FBS and added to 3 mL MethoCult. The vortexed
mixture was then dispensed into three 35-mm dishes at 1.1 mL per plate,
which were placed into a 100-mm culture dish and incubated at 37C, 5%
CO2 for 12 days. Colonies were counted on an inverted microscope (Carl
Zeiss Microscopy Thornwood, NY).
Flow Cytometric Analysis
The mAbs (Supplementary data) reactive with murine cell antigens
were purchased from BD Biosciences (San Jose, CA) or eBioscience (San
Diego, CA). Cell preparation and analysis were performed as previously
described [13]. Mouse HSCs were deﬁned as Lin-Sca-1þc-Kitþ (LSK) cells,
and Lin- (lineage negative) cells were gated as shown in Supplemental
Figure 1. The immune subsets were gated as CD3-NK1.1þ for natural killer
(NK) cells, CD3þCD25þFoxp3þ for regulatory T cells (Tregs),
B220-CD11cþCD11bþ for conventional dendritic cells (cDCs), and
CD11b-CD11clowPDCA1þSiglecHþ for plasmacytoid DCs (pDCs).
Statistics
For continuous endpoints, Student’s t-test was used to compare 2 in-
dependent groups. Measurements such as frequency and absolute number
LSK cells, colony formation, and absolute number of Tregs were logarith-
mically transformed to normalize the data and stabilize the variance. A 1-
way ANOVA model was applied to multiple comparisons, and a 2-way
ANOVA model was performed to evaluate the synergistic effect between
FLT3L and plerixafor. The log-rank test was used to compare survival curves.
All tests were 2 sided. P values were adjusted for multiple comparisons by
Holms’ procedure. P < .05 was considered as statistically signiﬁcant.
RESULTS
FP Effectively Mobilized LSK Cells into Peripheral Blood
To test the effect of the combination of FLT3L and pler-
ixafor (FP) on HSC mobilization, both the WBC counts and
HSCs (Lin-Sca-1þc-Kitþ, LSK cells, a hematopoietic stem
celleenriched population) in the peripheral blood wereanalyzed inmice subjected to various mobilization regimens,
including the combination of G-CSF and plerixafor (GP), one
of the strongest mobilizing regimens currently used in the
clinic. Cell counts showed that mice in the GP group had the
highest WBC counts and the FP group the second highest
(Supplemental Figure 2). Compared with PBS-treated mice,
plerixafor-treated mice had a modest up-regulation of LSK
cells, whereas FLT3L-treated mice mobilized signiﬁcantly
more LSK cells into the blood (Figure 1A). However, the FP
combination mobilized signiﬁcantly higher frequency and
greater absolute number of LSK cells, reaching up to 6-fold
and 12-fold higher than those of FLT3L alone, respectively
(Figure 1B,C). Statistical analysis revealed that FP showed a
synergistic mobilizing effect (P< .05, Supplemental Figure 3).
Although the mice from the GP group had the highest WBC
counts, the absolute number of LSK cells was similar to FLT3L
alone, because most WBC cells mobilized by GP were neu-
trophils (Supplemental Figure 4).
We also compared LSK cells mobilized by FPwith those by
G-CSF alone, which is the regimen most frequently used in
the clinic, and data demonstrated that FP mobilized signiﬁ-
cantly more LSK cells (Figure 1A-C P < .05). Colony formation
assays revealed that cells mobilized by FP contained signiﬁ-
cantly more colony-forming units than any other regimens,
including GP, FLT3L alone, and plerixafor alone (Figure 1D),
and a synergistic effect was also observed between FLT3L and
plerixafor (Supplemental Figure 5, P < .01).
FP Effectively Mobilized NK Cells, Tregs, and DCs into
Peripheral Blood
In addition to LSK cells, other immune cell subsets were
also assessed. Mobilization with FP or FLT3L alone signiﬁ-
cantly increased NK (CD3-NK1.1þ) cell percentages to the
same extent (Figure 2A,B), consistent with previous reports
of induction of NK cell expansion by FLT3L [14]. Importantly,
FP administration resulted in a muchmore dramatic increase
of NK cells in absolute number than FLT3L alone or any other
regimens (Figure 2B, right). Although none of the mobilizing
agents induced a signiﬁcant increase of Treg frequency
(Supplemental Figure 6), FP led to a signiﬁcantly higher ab-
solute number of Tregs in mobilized blood than the other
regimens (Figure 2C). In agreement with previous ﬁndings
that FLT3L is able to expand DCs both in vivo and in vitro
[15,16], the 2 major subsets of DCs, pDCs and cDCs, were both
signiﬁcantly increased in proportion for the FP group when
compared with GP (Figure 2D).
FP-Mobilized Grafts Signiﬁcantly Enhanced Survival of
Mice in Both Syngeneic and Allogeneic Settings
To test the clinical potential of FP-mobilized grafts, cells
mobilized by different regimens were transfused into
lethally irradiated syngeneic mice. Mice receiving grafts
mobilized by PBS, plerixafor alone, or G-CSF alone died
within 21 days, probably due to failure to reconstitute he-
matopoietic cells, because the frequencies of progenitor or
LSK cells were much lower in these groups (Figure 1A). This
indicates that fewer progenitor or LSK cells were trans-
planted for these groups when a consistent number of
mobilized cells were infused for each group. In contrast, mice
receiving FLT3L or FP-mobilized products survived 100% at
day 21, and the survival rate was maintained at approxi-
mately 70% as far out as 4 months after transplantation
(Figure 3A). The engraftment of the cells mobilized by FP was
signiﬁcantly superior to that of the cells mobilized by GP
(P < .05), with the latter having a survival rate of only 35% at
Figure 1. FP effectively mobilized LSK cells into peripheral blood. (A-C) Peripheral blood cells in mice treated with indicated mobilizing regimens were harvested,
subjected to RBC depletion, and stained for HSCs (Lin-Sca-1þc-Kitþ, LSK cells). The representative data from 1 of 9 mice with similar results are shown in A, and the
summary data of 3 mice in 1 of 3 experiments with similar data for the frequency (B) and the absolute number (C) of LSK cells are also shown. FP indicates the
combination of FLT3L and plerixafor, and GP denotes the combination of G-CSF and plerixafor. (D) Mobilized peripheral blood cells were prepared as in A and
subjected to colony formation assay. Shown are the summary data of 3 mice for the colony forming units larger than 200 cells. For all panels, *P < .05, **P < .01, and
error bars represent standard deviation.
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in the surviving mice also showed that mice receiving FP
grafts contained a higher frequency of LSK cells than those
receiving GP grafts (Supplemental Figure 7).
Next, we explored the transplantation efﬁcacy of the FP-
mobilized cells in an allogeneic transplantation model.
Lethally irradiated BALB/c mice were transplanted with pe-
ripheral blood cells mobilized by the different regimens from
C57BL/6 mice. Based on previous reports [11], more mobi-
lized peripheral blood cells were transplanted in this MHC-
mismatched model than in the above syngeneic model
(8  105 versus 2  105 cells per recipient). All recipients of
grafts mobilized by PBS, plerixafor alone, or G-CSF alone died
within 3 weeks after transplantation, whereas 80% and 66%
of mice receiving grafts mobilized by FP or FLT3L alone sur-
vived to 4 months post-transplantation, respectively
(Figure 3B). The survival rate of the FP groups was signiﬁ-
cantly higher than that observed in the GP group (12.5% alive
at 4 months post-transplantation, P< .05). At 4 months post-
transplantation, the mice in the FP group that remained
healthy were killed and found to have both long-term HSCs
(CD135-CD34- LSK) and short-term HSCs (CD135-CD34þLSK)
[17] originated from donor C57BL/6 mice (H2Kb) dominating
in bone marrow (Supplemental Figure 8), suggesting their
superior survivals may be due to the better hematopoietic
reconstitution resulting from enhanced stem cell mobiliza-
tion by this regimen.
DISCUSSION
Because mobilized peripheral blood stem cells were
demonstrated to have clinical advantages over bone marrow
stem cells for HSCT [18], extensive efforts have been invested
in the pursuit of optimal mobilizing regimens. Currently, G-
CSFebased regimens (alone or in combination withchemotherapy or other agents) are the most common
methods used to mobilize HSCs for autologous trans-
plantation. However, poor mobilization still remains an
important problem. In a study of 976 patients who went
through mobilization, 29.7% failed to achieve sufﬁcient
numbers of stem cells [19]. Here we report FP as a novel
regimen that is able to induce signiﬁcantly more robust HSC
mobilization, when compared with the current strongest
regimen in clinic, GP. In fact, FP leads to 6-fold increase in
frequency and 12-fold increase in absolute number of
phenotypically deﬁned stem cells mobilized into peripheral
blood (Figure 1). A recent clinical trial showed the safety and
efﬁciency of FLT3L alone in CD34þ stem cell mobilization in
healthy donors [5]. Considering the synergistic effect be-
tween FLT3L and plerixafor reported here, it is tempting to
speculate the likelihood of circumventing mobilization fail-
ure issue using this regimen in poor mobilizers. Indeed, the
lethally irradiated syngeneic mice were rescued with a small
amount of mobilized grafts by FP but not the regimens
currently used in the clinic (ie, G-CSF alone or GP) (Figure 3A),
further demonstrating the stem cellemobilizing potential of
this regimen.
The allogeneic transplantation setting, on the other hand,
requires a sufﬁcient number of HSCs as well as other cell
subsets to help overcome allogeneic transplantation-related
complications, such as GVHD and engraftment failure due to
allograft rejection. Here we showed that FP-mobilized grafts
signiﬁcantly improved the survival of mice after allogeneic
transplantation (Figure 3B). The superiority of FP to other
regimensmay be explained bymore HSCs as well as more NK
cells, Tregs, and DCs that were mobilized into peripheral
blood to suppress acute GVHD. NK cells have been demon-
strated to induce an antitumor response while suppressing
the development of GVHD in mice [20]. Tregs are important
Figure 2. FP effectively mobilized NK cells, Tregs, and DCs into peripheral blood. (A and B) Peripheral blood cells in mice treated with indicated mobilizing regimens
were harvested, subjected to RBC depletion, stained for NK cells, and subjected to ﬂow cytometric analysis. Shown are the representative (A) and the summary (B)
data of 3 mice in 1 of 3 experiments with similar results. (C) Mobilized peripheral blood cells were prepared as in A and subjected to ﬂow cytometric analysis for
Tregs. Shown are the summary data of 3 mice for the absolute number of Tregs. (D) GP- and FP-mobilized peripheral blood cells from 3 mice were pooled together
respectively and stained for cDCs (B220-CD11bþCD11cþ) and pDCs (CD11b-CD11clowPDCAþSiglecHþ). For all panels, *P < .05, **P < .01, and error bars represent
standard deviation.
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generate protective effects against GVHD after allogeneic
transplantation [21]. As a result, FP-mobilized grafts might
favor a better outcome in MHC-mismatched transplantationFigure 3. FP-mobilized grafts signiﬁcantly enhanced survival of mice in both syngene
(A) or BALB/c mice (B) receiving peripheral blood cells from C57BL/6 mice mobilized
served as a control group. A total of 2  105 (A) or 8  105 (B) peripheral blood cells w
test was used to compare survival curves. P values in A: FP versus GP, P < .05, FP versus
PBS, P < .001. P values in B: FP versus GP, P < .05, FP versus FLT3L, P ¼ .41, FP versuscomparedwith grafts mobilized by other regimens. Although
cDCs are generally considered to enhance GVHD [22], the
simultaneous increase of pDCs may attenuate the effect of
cDCs, because pDCshavebeen shown to inhibitGVHD [23,24].ic and allogeneic settings. Survival analysis of lethally irradiated C57BL/6 mice
by the indicated regimens. Irradiated mice without any cell infusion (IR Ctl)
ere transplanted for each recipient. Each group contains 5 to 8 mice. A log-rank
FLT3L, P ¼ .53, FP versus G-CSF, P < .01, FP versus plerixafor, P < .001, FP versus
G-CSF, P < .01, FP versus plerixafor, P < .01, FP versus PBS, P < .001.
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control groups of PBS, G-CSF alone, and GP,mice transplanted
with peripheral blood cells mobilized by FP had a lower
incidence of acute GVHD (characterized by hunched back,
inactivity, diarrhea, rufﬂed fur, and over 10% weight loss).
It is also noteworthy that compared with the cells mobi-
lized by other regimens, those mobilized by FP had consis-
tently higher numbers of Gr1medCD11bþ cells (Supplemental
Figure 4), which might be a population increasingly reported
to be involved in both autologous [25] and allogeneic [26]
stem cell transplantation as monocytic myeloid-derived
suppressor cells [27]. In allogeneic stem cell trans-
plantation, myeloid-derived suppressor cells might also
mitigate GHVD as NK and Tregs do. This could be another
explanation for the survival advantage observed in mice
infused with FP-mobilized cells, although the role of this
population in transplantation requires further study. There-
fore, we believe the immune cell subsets and the HSCs
mobilized by FP may act together to contribute to the
beneﬁcial transplantation outcome in the allogeneic mouse
model that we used.
In summary, in these preclinical studies, we describe a
novel potent cell mobilization regimen combining FLT3L and
plerixafor, which may have broad clinical applications in
both autologous and allogeneic transplantation. Future
clinical trials are warranted to further explore the potential
of this regimen.
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